A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

Phase Ia dose-escalation part of FB849 Monotherapy

Phase Ib dose-expansion of FB849 monotherapy

Phase IIb dose-escalation part of FB849 in Combination with Pembrolizumab

Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type A cancer)

Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type B cancer)

Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type C cancer)